Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors

Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion

(2013) Yared Hailemichael et al.   NATURE MEDICINE

Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma

(2012) Jürgen C. Becker et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial

(2012) Eva Ellebaek et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

T Cell Assays and MIATA: The Essential Minimum for Maximum Impact

(2012) C.M. Britten et al.   IMMUNITY

Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients

(2011) Hidekazu Kameshima et al.   CANCER SCIENCE

Induction of HLA-DP4–Restricted Anti-Survivin Th1 and Th2 Responses Using an Artificial Antigen-Presenting Cell

(2011) Makito Tanaka et al.   CLINICAL CANCER RESEARCH

Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients

(2011) Melanie Widenmeyer et al.   INTERNATIONAL JOURNAL OF CANCER

A methodological framework to enhance the clinical success of cancer immunotherapy

(2011) Axel Hoos et al.   NATURE BIOTECHNOLOGY

Altered decamer and nonamer from an HLA-A0201-restricted epitope of Survivin differentially stimulate T-cell responses in different individuals

(2011) Chantale Bernatchez et al.   VACCINE

Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma

(2010) A. P. Rapoport et al.   BLOOD

Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer

(2010) Akihiro Miyazaki et al.   CANCER SCIENCE

MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors

(2010) Matthias Leisegang et al.   JOURNAL OF CLINICAL INVESTIGATION

Phase I clinical study of anti-apoptosis protein survivin-derived peptide vaccination for patients with advanced or recurrent urothelial cancer

(2009) Ichiya Honma et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Baseline levels of CD8+ T cells against survivin and survivin-2B in the blood of lung cancer patients and cancer-free individuals

(2008) Vaios Karanikas et al.   CLINICAL IMMUNOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Therapeutic Dendritic Cell Vaccination of Patients With Metastatic Renal Cell Carcinoma

(2008) Annika Berntsen et al.   JOURNAL OF IMMUNOTHERAPY

Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer

(2008) Tetsuhiro Tsuruma et al.   Journal of Translational Medicine